Nasdaq
$9.60▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.69BShares out 4.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
36- 10.9Overnight26.10.09 09:59SCHEDULE 13D/AOwnership#●●●#●●●
Gossamer Bio, Inc.Bullish
D. E. Shaw affiliates, Cogence and Valence, consistently sold shares of Gossamer Bio, Inc. common stock between September 29, 2026, and October 8, 2026. During this period, the two entities reduced their holdings by disposing of over 20,000 shares in the market.…more
$9.60+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28After-hours26.09.29 08:49SCHEDULE 13D/AOwnership
Gossamer Bio, Inc.
D. E. Shaw-affiliated entities, Cogence and Valence Portfolios, continuously sold shares of Gossamer Bio between August 25, 2026, and September 28, 2026. During this period, both investment entities reduced their holdings in the company.…more
$9.60+0.00%vs prev closeView filingShare - 9.28After-hours26.09.29 05:018-KKey event
Gossamer Bio, Inc.
Gossamer Bio has regained compliance with the Nasdaq's minimum bid price requirement following a 1-for-80 reverse stock split effected on September 10, 2026. Consequently, Nasdaq notified the company on September 25, 2026, that the minimum bid price matter is now closed and the company remains in compliance with listing rules.…more
$9.60+0.00%vs prev closeView filingShare
35 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23After-hours26.09.24 05:02#●●●#●●●
Gossamer Bio Submits NDA to FDA for Seralutinib
Gossamer Bio has submitted a New Drug Application to the FDA for its pulmonary arterial hypertension treatment, seralutinib. The application is supported by Phase 3 clinical data, and the company now awaits the FDA's decision on filing acceptance.…more
$9.60+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.11Pre-market26.09.11 21:02
●●●●●●●● ●●●●● ●●●●●●
Gossamer Bio has announced a 1-for-80 reverse stock split to consolidate its outstanding shares. This move typically signals concerns regarding share price levels and potential liquidity issues.…more
$9.60+0.00%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 22:07
●●●●●●●● ●●●●● ●●●●●●
Gossamer Bio will implement a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split becomes effective after market close on September 10, with trading on a split-adjusted basis starting September 11.…more
$9.60+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report